Daily Medication Pearl: Lurasidone Hydrochloride (Latuda) for Schizophrenia
The efficacy of Latuda in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.
Medication Pearl of the Day: Lurasidone Hydrochloride (Latuda)
Indication: Latuda is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and adolescents, depressive episode associated with bipolar I disorder in adults and pediatric patients as monotherapy, and depressive episode associated with bipolar I disorder in adults as adjunctive therapy with lithium or valproate.
Insight:
- Dosing: Depending on the diagnosis, may start from 20 mg up to 160 mg per day.
- Dosage form: Tablets 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.
- Adverse events (AEs): Common AEs associated with Latuda are somnolence, akathisia, extrapyramidal symptoms, nausea, rhinitis, weight increase, and insomnia.
- Mechanism of action: Its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 receptor antagonism.
- Manufacturer: Sunovion
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025